NYSE:ABBVAbbVie Stock Price, Forecast & News

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ABBV shares have increased by 16.5% and is now trading at $98.88. View which stocks have been most impacted by Coronavirus.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 3 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AbbVie.

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, July 24th 2020. View our earnings forecast for AbbVie.

AbbVie Inc (NYSE:ABBV) released its earnings results on Friday, May, 1st. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.25 by $0.17. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.31 billion. AbbVie had a negative return on equity of 169.80% and a net margin of 24.77%. The firm's revenue was up 10.1% on a year-over-year basis. During the same period in the previous year, the company earned $2.14 earnings per share. View AbbVie's earnings history.

AbbVie declared a quarterly dividend on Wednesday, June 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $1.18 per share on Friday, August 14th. This represents a $4.72 dividend on an annualized basis and a yield of 4.77%. The ex-dividend date of this dividend is Tuesday, July 14th. View AbbVie's dividend history.

AbbVie declared that its Board of Directors has authorized a stock repurchase program on Thursday, December 13th 2018, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to reacquire up to 3.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.

AbbVie updated its FY 2020 After-Hours earnings guidance on Friday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50-50 billion.

17 equities research analysts have issued 12-month price targets for AbbVie's stock. Their forecasts range from $90.00 to $125.00. On average, they expect AbbVie's share price to reach $106.80 in the next year. This suggests a possible upside of 8.0% from the stock's current price. View analysts' price targets for AbbVie.

Media headlines about ABBV stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AbbVie earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about AbbVie.

Some companies that are related to AbbVie include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AbbVie investors own include Intact Financial (IFC), Constellation Software (CSU), AutoCanada (ACQ), Alimentation Couche-Tard (ATD.B), Vermilion Energy (VET), Wheaton Precious Metals (WPM), Rogers Communications (RCI), Open Text (OTEX), Bristol-Myers Squibb (BMY) and Valeant Pharmaceuticals Intl (VRX).

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

AbbVie's stock is owned by many different retail and institutional investors. Top institutional investors include Park National Corp OH (0.01%), Thomasville National Bank (0.01%), Red Spruce Capital LLC (0.00%), Cox Capital Mgt LLC (0.00%), Smithbridge Asset Management Inc. DE (0.00%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase. View institutional ownership trends for AbbVie.

ABBV stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, Birch Capital Management LLC, M&R Capital Management Inc., Red Spruce Capital LLC, Smithbridge Asset Management Inc. DE, and Thomasville National Bank. Company insiders that have sold AbbVie company stock in the last year include Jeffrey Ryan Stewart, and Timothy J Richmond. View insider buying and selling activity for AbbVie.

ABBV stock was purchased by a variety of institutional investors in the last quarter, including Nelson Van Denburg & Campbell Wealth Management Group LLC, Modus Advisors LLC, Cox Capital Mgt LLC, and Ellenbecker Investment Group. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase. View insider buying and selling activity for AbbVie.

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ABBV stock can currently be purchased for approximately $98.88.

AbbVie has a market capitalization of $146.02 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

The official website for AbbVie is www.abbvie.com.

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.